TellHerDoc review

A shared starting floor does not price two prescriptions

TellHerDoc advertises compounded semaglutide and tirzepatide with a general starting amount of $269. The public offer does not supply separate molecule or dose tables. It therefore should not be presented as a confirmed $269 ongoing price for every prescription of either drug. Ask which formulation, dose and supply period qualify and what subsequent treatment costs. A patient comparing an established prescription should obtain that actual quote, rather than assume the shared homepage floor matches her continuing treatment.

The banner offering $140 off is a discount amount, not a $140 medication price. It also does not establish a universal $129 opening charge merely by subtraction from the starting floor, because product and promotion eligibility remain unresolved. Request the selected offer's initial payment, regular rate and duration in writing. A discount can be genuine while still applying only to a particular plan, and the public information does not provide enough detail to combine every visible number into one dependable treatment budget.

Several forms need separate clinical and financial explanations

TellHerDoc describes standard and microdose choices and includes oral formats, including an orally disintegrating tablet, alongside its injectable programs. That variety can be relevant to a patient's preferences, but it should not turn the lowest general price into a quotation for every form. Ask the clinician to name the actual preparation and explain the instructions and rationale. A compounded tablet should not inherit FDA approval or trial claims from a branded oral product simply because both are described as needle free.

The same caution applies to microdosing. A smaller proposed dose is a distinct treatment approach to discuss, rather than an automatic safer substitute for a standard prescription or a reason to choose a plan by price alone. If the patient is changing medication or form, establish how the clinician handles that transition and follow-up. Familiar ingredient names do not make concentrations, administration instructions or clinical goals interchangeable. The financial order should describe the same product the clinician intends to prescribe, without leaving form selection implicit.

Fast fulfillment claims do not define continuing care

TellHerDoc advertises no monthly membership fee, prescribing within a day and free two-day delivery. Those are useful service claims to connect to the individual order, but they do not guarantee approval or medication arrival immediately after applying. Clinical review, dispensing and carrier delivery are separate stages. Ask how clarification is handled, when the delivery estimate begins and whom to contact about a delayed or problematic shipment. No separate membership fee also does not establish that all testing, visits or exceptional services are included.

No state list or detailed public postpartum, breastfeeding or PCOS pathway is established. Confirm eligibility in the actual consultation and delivery locations and discuss relevant history before buying. Cancellation and refund rules, including the cutoff for an order already in processing, also need an explicit explanation. TellHerDoc may be useful when a particular offered formulation fits a clinician-supported plan. Its affordability remains unresolved until the general $269 floor becomes a product-specific continuing quote, with the $140 discount, fulfillment claims and financial exit terms kept in their proper roles. The appropriate comparison begins only when those details describe a single actual offer.